Quality assurance in renal transplantation

  • Robert W. Steiner
Part of the Developments in Nephrology book series (DINE, volume 39)


The basics of quality assurance for renal transplant programs are as follows: (1) regular meetings of relevant transplant program personnel at which there are (2) brief reviews of the general scope of the committee’s responsibilities, (3) identification of specific problems, (4) monitoring of transplant program performance in those areas, (5) initiation of changes to improve performance, (6) evaluation of those changes. Confidentiality of proceedings is a practical requirement for transplant quality assurance meetings to insure that program defi- ciencies will receive full and frank analysis. Any quality assurance activity must be focused on selected issues and rely on the judgment of the transplant team to direct and prioritize its efforts. As the purpose of all quality assurance activities is patient benefit, it should be relatively easy to integrate meaningful quality assurance activities into a renal transplant program.


Quality Assurance Renal Transplantation Pneumocystis Carinii Pneumonia Continuous Quality Improvement Post Transplant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Berwick DM. Sounding board. Continuous improvement as an ideal in health care. New Engl J Med 1989; 320:53–6.PubMedCrossRefGoogle Scholar
  2. 4.
    Kasiske BL, Ramos EL, Gaston RS et al. The evaluation of renal transplant candidates: clinical practice guidelines. JASN 1995; 6:1–34.PubMedGoogle Scholar
  3. 5.
    Parfrey PS, Harnett JD and Barre PE. The natural history of myocardial disease in dialysis patients. J Am Soc Neph 1991; 2:2–12.Google Scholar
  4. 6.
    Rostand SG, Gretes JC, Kirk KA et al. Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis. Kidney Int 1979; 16:600–11.PubMedCrossRefGoogle Scholar
  5. 7.
    Hill MN, Grossman RA, Feldman HI et al. Original investigations. Changes in causes of death after renal transplantation, 1966 to 1987. Am J Kidney Dis 1991; 17:512–18.PubMedGoogle Scholar
  6. 8.
    Philipson JD, Carpenter BJ, Itzkoff J et al. Evaluation of cardiovascular risk for renal transplantation in diabetic patients. Am J Med 1986; 81:630–4.PubMedCrossRefGoogle Scholar
  7. 9.
    Holley JL, Fenton RA, Arthur RS et al. Thallium stress testing does not predict cardiovascular risk in diabetic patients with end stage renal disease undergoing cadaveric renal transplantation. Am J Med 1991; 90:563–70.PubMedGoogle Scholar
  8. 10.
    Burt RK, Gupta-Burt S, Suki WN et al. Reversal of left ventricular dysfunction after renal transplantation. Ann Int Med 1989; 111:635–40.PubMedGoogle Scholar
  9. 11.
    Parfrey PS, Forbes RDC, Hutchinson TA et al. The clinical and pathological course of hepatitis B liver disease in renal transplant recipients. Transplantation 1984; 37:461–6.PubMedCrossRefGoogle Scholar
  10. 12.
    Huang C, Lai M and Fong M. Hepatitis B liver disease in cyclosporine-treated renal allograft recipients. Transplantation 1990; 49:540–4.PubMedCrossRefGoogle Scholar
  11. 13.
    Fishman JA, Rubin RH, Koziel MJ et al. Hepatitis C virus and organ transplantation. Transplantation 1996; 62:147–54.PubMedCrossRefGoogle Scholar
  12. 14.
    Pereira BJG and Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51:981–99.PubMedCrossRefGoogle Scholar
  13. 15.
    Port FK, Ragheb NE, Schwartz AG et al. Neoplasms in dialysis patients: a population-based study. Am J Kidney Dis 1989; 14:119–23.PubMedGoogle Scholar
  14. 16.
    Ishikawa I, Saito Y, Shikura N et al. Ten-year prospective study on the development of renal cell carcinoma in dialysis patients. Am J Kidney Dis 1990; 16:452–8.PubMedGoogle Scholar
  15. 17.
    Penn I. The changing pattern of posttransplant malignancies. Transplantation Proc 1991; 23:1101 3.Google Scholar
  16. 18.
    Almond PS, Matas AJ, Gillingham K et al. Risk factors for second renal allografts immunosuppressed with cyclosporine, Transplantation 1991; 52:253–8.PubMedCrossRefGoogle Scholar
  17. 19.
    Bunce M, Young NT and Welsh KI. Molecular HLA typing — the brave new world. Transplantation 1997; 64:1505–13.PubMedCrossRefGoogle Scholar
  18. 20.
    Holley JL, Shapiro R, Lopatin WB et al. Obesity as a risk factor following cadaveric renal transplantation. Transplantation 1990; 49:387–9.PubMedCrossRefGoogle Scholar
  19. 21.
    Knight RJ, Schanzer H, Rand JH et al. Renal allograft thrombosis associated with the antiphospholipid antibody syndrome. Transplantation 1995; 60:614–15.PubMedCrossRefGoogle Scholar
  20. 22.
    Garvin PJ, Castadeda M, Linderer R et al. Management of hypercalcemic hyperparathyroidism after renal transplantation. Arch Surg 1985; 120: 578–83.PubMedGoogle Scholar
  21. 23.
    Dunn J, Golden D, Van Buren CT et al. Causes of graft loss beyond two years in the cyclosporine era. Transplantation 1990; 49:349 53.PubMedGoogle Scholar
  22. 24.
    Bertolatus JA. Renal transplantation for the nephrologist: living donor kidney transplantation: what did we learn during the 1980s? What should we learn during the 1990s? Am J Kid Dis 1991; 17:596–9.PubMedGoogle Scholar
  23. 25.
    Bia MJ, Ramos EL, Danovitch GM et al. Evaluation of living renal donors. Transplantation 1995; 60:322–327.PubMedCrossRefGoogle Scholar
  24. 26.
    Mohr DN, Offord KP, Owen RA et al. Asymptomatic microhematuria and urologie disease. A population-based study. J Am Med Ass 1986; 256:224–9.CrossRefGoogle Scholar
  25. 27.
    Rosenthal JT, Miserantino DP, Mendez R et al. Extending the criteria for cadaver kidney donors. Transplantation Proc 1990; 22:338–9.Google Scholar
  26. 28.
    Rao KV, Kasiske BL, Odlund MD et al. Influence of cadaver donor age on posttransplant renal function and graft outcome. Transplantation 1990; 49:91–5.PubMedCrossRefGoogle Scholar
  27. 29.
    Leunissen KML, Bosman FR, Nieman FHM et al. Amplification of the nephrotoxic effect of cyclosporine by preexistent chronic histological lesions in the kidney. Transplantation 1989; 48:590–3.PubMedGoogle Scholar
  28. 30.
    Finn WF. Prevention of ischemic injury in renal transplantation. Kidney Int 1990; 37:171–82.PubMedCrossRefGoogle Scholar
  29. 31.
    Tilney NL and Kirkman RL. Surgical aspects of kidney transplantation. In Garavoy MR and Guttmann RD, editors. Renal transplantation. Edinburgh, Churchill Livingstone, 1986; 93–123.Google Scholar
  30. 32.
    Belzer FO, Glass N and Sollinger H. Technical complications after renal transplantation. In Morris PJ, editor. Kidney transplantation, 3rd edition. Philadelphia, W.B. Saunders, 1988; 511–32.Google Scholar
  31. 33.
    Starzl TE, Broth CG, Putman CW et al. Urological complications in 216 human recipients of renal transplants. Ann Surg 1973; 172:609.Google Scholar
  32. 34.
    Wilszek HE. Percutaneous needle biopsy of the renal allograft. Transplantation 1990; 50:790–7.CrossRefGoogle Scholar
  33. 35.
    Roza AM, Gallagher-Lapek S, Johnson CP et al. Renal transplantation in patients more than 65 years old. Transplantation 1989; 48:689–725.PubMedGoogle Scholar
  34. 36.
    Pirsch JD, Stratta RJ, Armbrust MJ et al. Cadaveric renal transplantation with cyclosporine in patients more than 60 years of age. Transplantation 1989; 47:259–61.PubMedCrossRefGoogle Scholar
  35. 37.
    Dunn DL, Mayoral JL, Gillingham KJ et al. Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation 1991; 51:98–106.PubMedCrossRefGoogle Scholar
  36. 38.
    Munda R, Hutchins M et al. Infection in OKT3-treated patients receiving additional antirejection therapy. Transplantation Proc 1989; 21:1763–5.Google Scholar
  37. 39.
    Davis CL. In-depth review. The prevention of cytomegalo-virus disease in renal transplantation. Am J Kidney Dis 1990; 16:175 88.PubMedGoogle Scholar
  38. 40.
    Wade JC, Newton B, Flournoy N et al. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplant. Am Intern Med 1984; 100:823.Google Scholar
  39. 41.
    Rubin RH and Tolkoff-Rubin NE. Infections: the new problems. Transplantation Proc 1989; 21:1440–5.Google Scholar
  40. 42.
    Maddux MS, Veremis SA, Bauma WD et al. Effective prophylaxis of early posttransplant urinary tract infections (UTI) in the cyclosporine (CSA) era. Transplantation Proc 1989; 21: 2108–9.Google Scholar
  41. 43.
    Higgins RM, Bloom SL, Hopkin JM et al. The risks and benefits of low-dose cotrimoxazole prophylaxis for pneumocystis pneumonia in renal transplantation. Transplantation 1989; 47:558–60.PubMedCrossRefGoogle Scholar
  42. 44.
    Tesi RJ, Kano JM, Horn HR et al. Thymoglobulin reverses acute renal allograft rejection better than ATGAM — a double-blinded randomized clinical trial. Transplantation Proc 1997; 29:S21–3.CrossRefGoogle Scholar
  43. 45.
    Soulillou JP. Relevant targets for therapy with monoclonal antibodies in allograft transplantation. Kidney Int 1994; 46:540–53.PubMedCrossRefGoogle Scholar
  44. 46.
    First MR. An update on new immunosuppressive drugs undergoing preclinical and clinical trials: Potential applications in organ transplantation. Am J Kid Dis 1997; 29:303–17.PubMedGoogle Scholar
  45. 47.
    Peraldi MN, Akposso K, Haymann JP et al. Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation. Transplantation 1996; 62:1670–3.PubMedCrossRefGoogle Scholar
  46. 48.
    Cho YW and Cecka JM. Organ procurement organization and transplant center effects on cadaver renal transplant outcomes. In Cecka KM and Terasaki PI, editors. Clinical transplants 1996. Los Angeles, UCLA Tissue Typing Laboratory, 1997.Google Scholar
  47. 49.
    Helderman JH, Van Buren DH, Amend WJC et al. Chronic immunosuppression of the renal transplant patient. JASN 1994;4:S2–S9.PubMedGoogle Scholar
  48. 50.
    Keown P, Landsberg D, Halloran P et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Transplantation 1996; 62:1744.PubMedCrossRefGoogle Scholar
  49. 51.
    St Sinclair NR. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. Can Med Assoc J 1992; 147:645–57.Google Scholar
  50. 52.
    Hricik DE, Kupin WL and First MR. Steroid-free immunosuppression after renal transplantation. JASN 1994; 4:S10–16.Google Scholar
  51. 53.
    Lindholm A and Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54:205.PubMedCrossRefGoogle Scholar
  52. 54.
    Woodle ES, Cronin D, Newell KA et al. Tacrolimus therapy for refractory acute renal allograft rejection. Transplantation 1996; 62:906–10.PubMedCrossRefGoogle Scholar
  53. 55.
    Bruan WE. Long-term complications of renal transplantation. Kidney Int 1990; 37:1363–78.CrossRefGoogle Scholar
  54. 56.
    Mahony JF, Caterson RJ, Pollock CA et al. Coronary artery disease is the major late complication of successful cadaveric renal transplantation. Clin Transplantation 1990; 4:129–32.Google Scholar
  55. 57.
    Kasiske BL, Tortorice KL, Heim-Duthoy KL et al. Lovastatin treatment of hypercholesterolemia in renal transplant recipients. Transplantation 1990; 49:95 100.PubMedCrossRefGoogle Scholar
  56. 58.
    Glicklich DG, Tellis VA, Quinn T et al. Comparison of captopril scan and doppler ultrasonography as screening tests for transplant renal artery stenosis. Transplantation 1990; 49:217–19.PubMedCrossRefGoogle Scholar
  57. 59.
    Palmer BF, Dawidson I, Sagalowsky A et al. Improved outcome of cadaveric renal transplantation due to calcium channel blockers. Transplantation 1991; 52:640–5.PubMedCrossRefGoogle Scholar
  58. 60.
    Mathew TH: In-depth review. Recurrence of disease following renal transplantation. Am J Kidney Dis 1988; 12:85–96.PubMedGoogle Scholar
  59. 61.
    Mayer AD, Dmitrewski J, Squifflet JP et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation 1997; 64:436–43.PubMedCrossRefGoogle Scholar
  60. 63.
    Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. NEJM 1998; 338:161–6.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Robert W. Steiner

There are no affiliations available

Personalised recommendations